Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions

Journal of Clinical Immunology

Volumn 34, Issue 2, 2014, Pages 245-255

  Geluk, Annemieke ^a   Van Meijgaarden, Krista E ^a   Wilson, Louis ^a   Bobosha, Kidist ^a,b   Van Der Ploeg Van Schip, Jolien J ^a   Van Den Eeden, Susan J F ^a   Quinten, Edwin ^a   Dijkman, Karin ^a   Franken, Kees L M C ^a   Haisma, Elisabeth M ^a   Haks, Mariëlle C ^a   Van Hees, Colette L M ^c   Ottenhoff, Tom H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; early diagnosis; gene profiles; leprosy reactions; T1R

Indexed keywords

CD68 ANTIGEN; CLOBETASOL PROPIONATE; CLOFAZIMINE; CXCL9 CHEMOKINE; DAPSONE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHOTREXATE; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; OFLOXACIN; PREDNISOLONE; RIFAMPICIN; RNA; STEROID; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADOLESCENT; ARTICLE; CASE REPORT; CD39+ CCL4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; ERYTHEMA NODOSUM LEPROSUM; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; KERATINOCYTE; LONGITUDINAL STUDY; LOW DRUG DOSE; MALE; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; PAIN; PRIORITY JOURNAL; SKIN BIOPSY; T LYMPHOCYTE SUBPOPULATION; TYPE 1 LEPROSY REACTION; UPREGULATION;

ADOLESCENT; ANTIGENS, BACTERIAL; BIOLOGICAL MARKERS; BIOPSY; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOPHENOTYPING; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; RNA, MESSENGER; SKIN; T-LYMPHOCYTE SUBSETS; TRANSCRIPTOME;

EID: 84898843454     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-013-9979-x     Document Type: Article

References (39)

1. Leprosy update, 2011. Wkly Epidemiol Rec. 2011 Sep 2;86(36):389-99.
2. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255-73.
3. Massone C, Clapasson A, Nunzi E. Borderline lepromatous leprosy in an Italian man. Am J Trop Med Hyg. 2013;88(2):211.
4. Britton WJ, Lockwood DN. Leprosy. Lancet. 2004;363(9416):1209-19.
5. Lockwood DN, Suneetha L, Sagili KD, Chaduvula MV, Mohammed I, van Brakel W, et al. Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort. PLoS Negl Trop Dis. 2011;5(12):e1327.
6. Raffe SF, Thapa M, Khadge S, Tamang K, Hagge D, Lockwood DN. Diagnosis and treatment of leprosy reactions in integrated services - the patients' perspective in Nepal. PLoS Negl Trop Dis. 2013;7(3):e2089.
7. van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev. 2005;76(1):14-34.
8. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol. 1991;84(1):103-8.
9. Stefani MM, Guerra JG, Sousa AL, Costa MB, Oliveira ML, Martelli CT, et al. Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report. BMC Infect Dis. 2009;9:75.
10. Scollard DM, Chaduvula MV, Martinez A, Fowlkes N, Nath I, Stryjewska BM, et al. Increased CXC ligand 10 levels and gene expression in type 1 leprosy reactions. Clin Vaccine Immunol. 2011;18(6):947-53.
11. Moraes MO, Sampaio EP, Nery JA, Saraiva BC, Alvarenga FB, Sarno EN. Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol. 2001;144(1):175-81.
12. Geluk A. Challenges in immunodiagnostic tests for leprosy. Expert Opin Med Diagn. 2013;7(3):265-74.
13. Silva EA, Iyer A, Ura S, Lauris JR, Naafs B, Das PK, et al. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health. 2007;12(12):1450-8.
14. Iyer A, Hatta M, Usman R, Luiten S, Oskam L, Faber W, et al. Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin Exp Immunol. 2007;150(2):210-6.
15. Geluk A, Bobosha K, van der Ploeg-van Schip JJ, Spencer JS, Banu S, Martins SB, et al. New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. J Immunol. 2012;188(10):4782-91.
16. Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, Jacobsen M, et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun. 2012;13(1):71-82.
17. Commandeur S, van Meijgaarden KE, Prins C, Pichugin AV, Dijkman K, van den Eeden SJ, et al. An unbiased genome-wide mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J Immunol. 2013;190(4):1659-71.
18. Spaans VM, Peters AA, Fleuren GJ, Jordanova ES. HLA-E expression in cervical adenocarcinomas: association with improved long-term survival. J Transl Med. 2012;10:184.
19. Sahiratmadja E, Alisjahbana B, de Boer T, Adnan I, Maya A, Danusantoso H, et al. Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun. 2007;75(2):820-9.
20. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010;466(7309):973-7.
21. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A. 2004;101(13):4560-5.
22. Savage ND, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk A, et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J Immunol. 2008;181(3):2220-6.
23. Joosten SA, van Meijgaarden KE, Savage ND, de Boer T, Triebel F, van der Wal A, et al. Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A. 2007;104(19):8029-34.
24. Zhang L, Zhao Y. The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol. 2007;211(3):590-7.
25. Cogen AL, Walker SL, Roberts CH, Hagge DA, Neupane KD, Khadge S, et al. Human Beta-defensin 3 is up-regulated in cutaneous leprosy type 1 reactions. PLoS Negl Trop Dis. 2012;6(11):e1869.
26. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science. 2013;339(6126):1448-53.
27. Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol. 2012;20(9):419-28.
28. Zhang FR, Huang W, Chen SM, Sun LD, Liu H, Li Y, et al. Genomewide association study of leprosy. N Engl J Med. 2009;361(27):2609-18.
29. Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med. 2009;9:21.
30. Friedman DJ, Kunzli BM, Rahim YI, Sevigny J, Berberat PO, Enjyoji K, et al. From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A. 2009;106(39):16788-93.
31. Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff TH, Joosten SA. CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8 CD39 regulatory T cells. Eur J Immunol. 2013;43(7):1925-32.
32. de Cassan SC, Pathan AA, Sander CR, Minassian A, Rowland R, Hill AV, et al. Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A. Clin Vaccine Immunol. 2010;17(7):1066-73.
33. Misch EA, Macdonald M, Ranjit C, Sapkota BR, Wells RD, Siddiqui MR, et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl Trop Dis. 2008;2(5):e231.
34. Brull F, Mensink RP, Steinbusch MF, Husche C, Lutjohann D, Wesseling GJ, et al. Beneficial effects of sitostanol on the attenuated immune function in asthma patients: results of an in vitro approach. PLoS ONE. 2012;7(10):e46895.
35. Lee JH, Lydon JP, Kim CH. Progesterone suppresses the mTOR pathway and promotes generation of induced regulatory T cells with increased stability. Eur J Immunol. 2012;42(10):2683-96.
36. Ochoa MT, Stenger S, Sieling PA, Thoma-Uszynski S, Sabet S, Cho S, et al. T-cell release of granulysin contributes to host defense in leprosy. Nat Med. 2001;7(2):174-9.
37. Rodrigues LS, Hacker MA, Illarramendi X, Pinheiro MF, Nery JA, Sarno EN, et al. Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy. BMC Infect Dis. 2011;11:339.
38. Zhao C, Takita J, Tanaka Y, Setou M, Nakagawa T, Takeda S, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell. 2001;105(5):587-97.
39. McLeod RS, Taylor DW, Cohen Z, Cullen JB. Single-patient randomised clinical trial. Use in determining optimum treatment for patient with inflammation of Kock continent ileostomy reservoir. Lancet. 1986;1(8483):726-8.